<?xml-stylesheet type="text/xsl" href="ViewNLM-v2.3.xsl"?><!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Korean Med Sci</journal-id><journal-id journal-id-type="publisher-id">JKMS</journal-id><journal-title-group><journal-title>Journal of Korean Medical Science</journal-title></journal-title-group><issn pub-type="ppub">1011-8934</issn><issn pub-type="epub">1598-6357</issn><publisher><publisher-name>The Korean Academy of Medical Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19543515</article-id><article-id pub-id-type="doi">10.3346/jkms.2009.24.3.493</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Differential Methylation Pattern of <italic>ID4</italic>, <italic>SFRP1</italic>, and <italic>SHP1</italic> between Acute Myeloid Leukemia and Chronic Myeloid Leukemia</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Uhm</surname><given-names>Kyung-Ok</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Eun Soo</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Yun Mi</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Jeong Seon</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Seok Jin</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Byung Soo</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Hyeon Soo</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Park</surname><given-names>Sun-Hwa</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Institute of Human Genetics, Department of Anatomy, Brain Korea 21 Biomedical Sciences, Korea University College of Medicine, Seoul, Korea.</aff><aff id="A2"><label>2</label>Division of Hematology/Oncology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.</aff><author-notes><corresp> Address for correspondence: Sun-Hwa Park, M.D. Department of Anatomy, Korea University College of Medicine, 126-1 Anam-dong 5-ga, Seongbuk-gu, Seoul 136-705, Korea. Tel: +82.2-920-6152, Fax: +82.2-929-5696, <email>parksh@korea.ac.kr</email></corresp></author-notes><pub-date pub-type="ppub"><month>6</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>18</day><month>6</month><year>2009</year></pub-date><volume>24</volume><issue>3</issue><fpage>493</fpage><lpage>497</lpage><history><date date-type="received"><day>11</day><month>1</month><year>2008</year></date><date date-type="accepted"><day>17</day><month>7</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 The Korean Academy of Medical Sciences</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">http://creativecommons.org/licenses/by-nc/3.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>To gain insight into the differential mechanism of gene promoter hypermethylation in acute and chronic leukemia, we identified the methylation status on one part of 5'CpG rich region of 8 genes, <italic>DAB2IP</italic>, <italic>DLC-1</italic>, <italic>H-cadherin</italic>, <italic>ID4</italic>, <italic>Integrin &#x003b1;4</italic>, <italic>RUNX3</italic>, <italic>SFRP1</italic>, and <italic>SHP1</italic> in bone marrows from acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) patients. Also, we compared the methylation status of genes in AML and CML using methylation-specific PCR (MSP). The frequencies of DNA methylation of <italic>ID4</italic>, <italic>SFRP1</italic>, and <italic>SHP1</italic> were higher in AML patients compared to those in CML patients. In contrast, no statistical difference between AML and CML was detected for other genes such as <italic>DLC-1</italic>, <italic>DAB2IP</italic>, <italic>H-cadherin</italic>, <italic>Integrin &#x003b1;4</italic>, and <italic>RUNX3</italic>. Taken together, these results suggest that these methylation-controlled genes may have different roles in AML and CML, and thus, may act as a biological marker of AML.</p></abstract><kwd-group><kwd>Leukemia, Myeloid, Acute</kwd><kwd>Chronic, BCR-ABL Positive</kwd><kwd>DNA Methylation</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Genomic DNA hypomethylation has been observed in the peripheral blood mononuclear cells of leukemia patients and in tumor cells of patients with B-cell lymphoproliferative diseases (<xref ref-type="bibr" rid="B1">1</xref>). DNA methylation may affect karyotypic stability, may influence euchromatin-heterochromatin interactions, and has been correlated with disease progression (<xref ref-type="bibr" rid="B2">2</xref>). On the other hand, promoters of some tumor suppressive genes are often hypermethylated (<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B6">6</xref>). For example, some patients with lymphomas do not express tumor suppressor genes because the promoters of these genes are methylated.</p><p>Leukemia is a hematological cancer of the bone marrow and lymphatic system. In leukemia, bone marrow produces a large number of abnormal white blood cells, which overwhelm the other types of blood cells, including red blood cells and platelets, thus impairing the production of normal white blood cells. In clinical classification, leukemia can be classified as acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). AML is a serious and lethal disease that affects adults. CML is a clonal disease of stem cell origin that is characterized by the presence of the Philadelphia chromosome (Ph+), which has been named t(9,22)(q34:q11). Its fusion gene product, Bcr-Abl, is a constitutively active tyrosine kinase. These facts suggest that somewhat different mechanisms may be involved in AML and CML. Nevertheless, the differential factors through which they produce a different type of leukemia are not yet completely understood.</p><p>In hematopoietic malignancies, hypermethylation of several genes including <italic>E-cadherin</italic>, <italic>DAP kinase</italic>, estrogen receptor (<italic>ER</italic>) alpha, and <italic>p15<sup>INK4B</sup></italic> are associated with gene inactivation (<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B10">10</xref>). Genes, such as <italic>DAB2IP</italic>, <italic>DLC-1</italic>, <italic>H-cadherin</italic>, <italic>ID4</italic>, <italic>Integrin &#x003b1;4</italic>, <italic>RUNX3</italic>, <italic>SFRP1</italic>, and <italic>SHP1</italic>, has been identified as being implicated in aberrant DNA methylation during development of human malignancy (<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B18">18</xref>). In order to gain insight into the differential epigenetic alterations in leukemia, we investigated the methylation statuses at selected locus of these genes in AML and CML patients using a methylation-specific polymerase chain reaction (MSP).</p></sec><sec sec-type="methods"><title>MATERIALS AND METHODS</title><sec><title>Sample collection</title><p>Diagnostic bone marrow samples were obtained from 23 patients with AML and 21 patients with CML. The samples were gathered by the Division of Hematology/Oncology (Department of Internal Medicine, Korea University Medical Center, Seoul, Republic of Korea) and analyzed by pathologist. Institutional review board approval and informed consent were obtained (KUMC-IRB-2006011-P-1, KUMCIRB-2006012-P-2). Of the AML patients, 17 males and 6 females were included, with ages ranging from 26 to 78 yr, at a median age of 45.61 (SD, 15.56) yr. Of the CML patients, 11 males and 10 females were included, with ages ranging from 18 to 75 yr (mean&#x000b1;SD, 49.91&#x000b1;16.53). As controls, 22 normal peripheral bloods were obtained from healthy volunteers (11 males and 10 females) ranging from 20 to 78 yr of age (mean&#x000b1;SD, 45.36&#x000b1;20.64).</p></sec><sec><title>Sodium bisulfite treatment and MSP</title><p>Chemical modification was performed as described previously, with minor modifications (<xref ref-type="bibr" rid="B19">19</xref>). In brief, 1 &#x000b5;g of genomic DNA was denatured by incubation with 0.2 M NaOH for 10 min at 37&#x02103;, followed by the addition of 550 &#x000b5;L of 3 M sodium bisulfite (pH 5.0) (Sigma, St. Louis, MO, U.S.A.) and 10 mM hydroquinone (Sigma), which was brought to a final volume of 600 &#x000b5;L. The mixtures were incubated at 55&#x02103; for 16 hr, and the modified DNA was then desalted with the Wizard Clean-Up system (Promega Corp., Madison, WI, U.S.A.). We performed polymerase chain reaction (PCR) using specific PCR primers capable of distinguishing between methylated and unmethylated DNA sequences. The primers for the unmethylated and methylated DNA sequences, PCR product size, and annealing temperature are shown in <xref ref-type="table" rid="T1">Table 1</xref>. The MSP primer sets were selected at the 5'-CpG island regions of genes using the MethPrimer software (<ext-link ext-link-type="uri" xlink:href="www.urogene.org">www.urogene.org</ext-link>). The PCR conditions were as follows: initial denaturation and hot start at 95&#x02103; for 5 min, and cycles consisting of 30 sec at 95&#x02103;, 30 sec at the annealing temperature, and 30 sec at 72&#x02103;. In addition, SCK, a human cholangiocarcinoma cell line, was used as positive control for Integrin &#x003b1;4 gene (<xref ref-type="bibr" rid="B20">20</xref>).</p></sec><sec><title>Statistical analysis</title><p>MSP results were analyzed as a dichotomous variable based on the presence or absence of gene methylation. The MSP results of tumor and normal samples were compared and analyzed with the Pearson chi-square test (Version 12; SPSS Inc., Chicago, IL, U.S.A.). Statistical significance was defined as a <italic>P</italic> value of &#x0003c;0.05.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>The multiple genes were found to be methylated in bone marrow from patients with AML or CML. Specifically, the frequencies of promoter hypermethylation at selected locus in the 23 AML samples were: 78.3% (18/23) for <italic>SHP1</italic>, 65.2% (15/23) for <italic>ID4</italic> and <italic>SFRP1</italic>, 26.1% (6/23) for <italic>H-cadherin</italic>, 8.7% (2/23) for <italic>DLC-1</italic>, and 4.3% (1/23) for <italic>DAB2IP</italic> and <italic>RUNX3</italic>. The frequencies of DNA hypermethylation at selected locus in the 21 CML samples were: 28.6% (6/21) for <italic>SHP1</italic>, 19.0% (4/21) for <italic>H-Cadherin</italic>, 14.3% (3/21) for <italic>ID4</italic>, 9.5% for (2/21) for <italic>SFRP1</italic>, and 0% (0/21) for <italic>DAB2IP</italic>, <italic>DLC-1</italic>, <italic>Integrin &#x003b1;4</italic>, and <italic>RUNX3</italic> (<xref ref-type="fig" rid="F1">Fig. 1</xref>). However, promoter hypermethylation of the 22 normal peripheral bloods was observed less frequently (<xref ref-type="table" rid="T2">Table 2</xref>).</p><p>There was a statistically significant difference between normal peripheral bloods and AML with respect to the frequencies of methylation of <italic>ID4</italic>, <italic>SFRP1</italic>, and <italic>SHP1</italic> (Pearson chi-square test; <italic>P</italic>&#x0003c;0.0001, <italic>P</italic>&#x0003c;0.0001, and <italic>P</italic>&#x0003c;0.0001, respectively) and between normal peripheral bloods and CML with respect to the frequencies of <italic>SHP1</italic> methylation (Pearson chi-square test; <italic>P</italic>=0.007). Furthermore, there was a statistically significant difference between the DNA methylation frequencies of AML patients and CML patients. The frequencies of DNA methylation of <italic>ID4</italic>, <italic>SFRP1</italic>, and <italic>SHP1</italic> were higher in AML compared to those in CML (<italic>P</italic>=0.001, <italic>P</italic>&#x0003c;0.0001, and <italic>P</italic>=0.001, respectively) (<xref ref-type="table" rid="T2">Table 2</xref>). In contrast, no statistical differences between AML and CML were detected in other genes such as <italic>DLC-1</italic>, <italic>DAB2IP</italic>, <italic>H-cadherin</italic>, <italic>Integrin &#x003b1;4</italic>, and <italic>RUNX3</italic>. Promoter methylation results at selected locus of eight genes with MSP method were shown in <xref ref-type="fig" rid="F1">Fig. 1</xref>. These results suggest that there may be differential epigenetic modification between AML and CML.</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Differential epigenetic alteration is observed in AML and CML patients. The results of the present study demonstrate the substantially increased frequency of promoter hypermethylation in <italic>ID4</italic>, <italic>SFRP1</italic>, and <italic>SHP1</italic> genes in AML compared to CML.</p><p>Leukemia, a heterogeneous group of hematopoietic malignancies that occur worldwide, includes acute and chronic myeloid leukemia. Despite many important advances in understanding the different biological and cytogenetic aspects of acute and chronic leukemia, a number of questions remained unanswered. It is understood that some kinds of leukemia present specific cytogenetic alterations (<xref ref-type="bibr" rid="B21">21</xref>). Different types of leukemia usually have specific epigenetic modifications that cause the activation of oncogenes and, in particular, the formation of abnormal fusion genes such as <italic>AML1-ETO</italic> (<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>), a fusion protein resulting from t(8,21) translocation that commonly occurs in AML. Another typical example is the fact that Bcr-Abl is a constitutively active, cytoplasmic tyrosine kinase that is generated by t(9;22) translocation in more than 95% of CML (<xref ref-type="bibr" rid="B24">24</xref>).</p><p>The central role of epigenetic modification of these genes in leukemia development promoted them as reasonable targets for understanding the differential mechanism between acute and chronic leukemia. In the present study, <italic>ID4</italic>, <italic>SFRP1</italic>, and <italic>SHIP1</italic> were hypermethylated in AML compared to CML. These results suggest that the epigenetic modification of these genes may play specific roles in the development of AML rather than CML and, thus, promoted them as ideal targets for drug development to treat AML. In the future, it is clearly imperative to understand the patho-physiological differential mechanisms of these genes in AML, and to finally explore novel therapeutic strategies.</p><p>In present study, methylation frequencies of <italic>SHP1</italic> gene were the high detected in CML as well as AML. <italic>SHP1</italic> is a member of the SHP family of proteins, cytoplasmic protein tyrosine phosphatase (PTP), and has been known as a candidate tumor suppressor gene in lymphoma, leukemia and other cancers (<xref ref-type="bibr" rid="B25">25</xref>). Also, the hypermethylation of <italic>SHP1</italic> gene was frequently detected in several human cancers and the reduced expression of the <italic>SHP1</italic> gene in various types of leukemias and lymphomas mainly occurred by promoter methylation (<xref ref-type="bibr" rid="B26">26</xref>-<xref ref-type="bibr" rid="B28">28</xref>). Therefore, these results indicate that aberrant DNA methylation of <italic>SHP1</italic> gene may be related to the tumorigenicity of myeloid leukemia.</p><p>The methylation frequencies of the <italic>DAB2IP</italic>, <italic>DLC-1</italic>, and <italic>RUNX3</italic> genes were detected at different levels in acute and chronic leukemia patients; however, the difference was negligible. In some genes like <italic>Integrin &#x003b1;4</italic> gene, the promoter methylation was not observed in most of the cases. However, hypermethylation of these genes was frequent event in esophageal squamous cell carcinomas, lung cancers, and gastric cancers (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>). Thus, DNA methylation of these genes may be not related to tumorigenicity of AML/CML in contrast with other cancers.</p><p>In summary, we have identified that aberrant DNA methylation of <italic>SHP1</italic> is a frequent event in AML and CML. Also, the frequencies of DNA methylation of several methylation-controlled genes, including <italic>ID4</italic>, <italic>SFRP1</italic>, and <italic>SHP1</italic>, were higher in AML patients compared to those in CML patients. Although these results should be confirmed, more comprehensive studies are necessary involving various known risk factors such as smoking and occupational carcinogens, and genetic susceptibilities. Our results suggest that aberrant DNA methylation of <italic>SHP1</italic> may be related to the tumorigenicity of AML and CML and hypermethylation of <italic>ID4</italic>, <italic>SFRP1</italic>, and <italic>SHP1</italic> genes may contribute to the pathogenesis mechanism of AML specifically.</p></sec></body><back><fn-group><fn fn-type="supported-by"><p>This study was supported by <funding-source>Korea University College of Medicine</funding-source> grant.</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wahlfors</surname><given-names>J</given-names></name><name><surname>Hiltunen</surname><given-names>H</given-names></name><name><surname>Heinonen</surname><given-names>K</given-names></name><name><surname>Hamalainen</surname><given-names>E</given-names></name><name><surname>Alhonen</surname><given-names>L</given-names></name><name><surname>Janne</surname><given-names>J</given-names></name></person-group><article-title>Genomic hypomethylation in human chronic lymphocytic leukemia</article-title><source>Blood</source><year>1992</year><volume>80</volume><fpage>2074</fpage><lpage>2080</lpage><pub-id pub-id-type="pmid">1382719</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehrlich</surname><given-names>M</given-names></name></person-group><article-title>DNA methylation in cancer: too much, but also too little</article-title><source>Oncogene</source><year>2002</year><volume>21</volume><fpage>5400</fpage><lpage>5413</lpage><pub-id pub-id-type="pmid">12154403</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daskalakis</surname><given-names>M</given-names></name><name><surname>Nguyen</surname><given-names>TT</given-names></name><name><surname>Nguyen</surname><given-names>C</given-names></name><name><surname>Guldberg</surname><given-names>P</given-names></name><name><surname>Kohler</surname><given-names>G</given-names></name><name><surname>Wijermans</surname><given-names>P</given-names></name><name><surname>Jones</surname><given-names>PA</given-names></name><name><surname>Lubbert</surname><given-names>M</given-names></name></person-group><article-title>Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment</article-title><source>Blood</source><year>2002</year><volume>100</volume><fpage>2957</fpage><lpage>2964</lpage><pub-id pub-id-type="pmid">12351408</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fulop</surname><given-names>Z</given-names></name><name><surname>Csernus</surname><given-names>B</given-names></name><name><surname>Timar</surname><given-names>B</given-names></name><name><surname>Szepesi</surname><given-names>A</given-names></name><name><surname>Matolcsy</surname><given-names>A</given-names></name></person-group><article-title>Microsatellite instability and hMLH1 promoter hypermethylation in Richter's transformation of chronic lymphocytic leukemia</article-title><source>Leukemia</source><year>2003</year><volume>17</volume><fpage>411</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">12592341</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graff</surname><given-names>JR</given-names></name><name><surname>Herman</surname><given-names>JG</given-names></name><name><surname>Myohanen</surname><given-names>S</given-names></name><name><surname>Baylin</surname><given-names>SB</given-names></name><name><surname>Vertino</surname><given-names>PM</given-names></name></person-group><article-title>Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><fpage>22322</fpage><lpage>22329</lpage><pub-id pub-id-type="pmid">9268383</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyko</surname><given-names>F</given-names></name><name><surname>Brown</surname><given-names>R</given-names></name></person-group><article-title>DNA methyltransferase inhibitors and the development of epigenetic cancer therapies</article-title><source>J Natl Cancer Inst</source><year>2005</year><volume>97</volume><fpage>1498</fpage><lpage>1506</lpage><pub-id pub-id-type="pmid">16234563</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herman</surname><given-names>JG</given-names></name><name><surname>Civin</surname><given-names>CI</given-names></name><name><surname>Issa</surname><given-names>JP</given-names></name><name><surname>Collector</surname><given-names>MI</given-names></name><name><surname>Sharkis</surname><given-names>SJ</given-names></name><name><surname>Baylin</surname><given-names>SB</given-names></name></person-group><article-title>Distinct patterns of inactivation of p15<sup>INK4B</sup> and p16<sup>INK4A</sup> characterize the major types of hematological malignancies</article-title><source>Cancer Res</source><year>1997</year><volume>57</volume><fpage>837</fpage><lpage>841</lpage><pub-id pub-id-type="pmid">9041182</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katzenellenbogen</surname><given-names>RA</given-names></name><name><surname>Baylin</surname><given-names>SB</given-names></name><name><surname>Herman</surname><given-names>JG</given-names></name></person-group><article-title>Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies</article-title><source>Blood</source><year>1999</year><volume>93</volume><fpage>4347</fpage><lpage>4353</lpage><pub-id pub-id-type="pmid">10361133</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melki</surname><given-names>JR</given-names></name><name><surname>Vincent</surname><given-names>PC</given-names></name><name><surname>Brown</surname><given-names>RD</given-names></name><name><surname>Clark</surname><given-names>SJ</given-names></name></person-group><article-title>Hypermethylation of E-cadherin in leukemia</article-title><source>Blood</source><year>2000</year><volume>95</volume><fpage>3208</fpage><lpage>3213</lpage><pub-id pub-id-type="pmid">10807790</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>MH</given-names></name><name><surname>Chung</surname><given-names>YF</given-names></name><name><surname>Lo</surname><given-names>KW</given-names></name><name><surname>Wickham</surname><given-names>NW</given-names></name><name><surname>Lee</surname><given-names>JC</given-names></name><name><surname>Huang</surname><given-names>DP</given-names></name></person-group><article-title>Frequent hypermethylation of p16 and p15 genes in multiple myeloma</article-title><source>Blood</source><year>1997</year><volume>89</volume><fpage>2500</fpage><lpage>2506</lpage><pub-id pub-id-type="pmid">9116295</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yano</surname><given-names>M</given-names></name><name><surname>Toyooka</surname><given-names>S</given-names></name><name><surname>Tsukuda</surname><given-names>K</given-names></name><name><surname>Dote</surname><given-names>H</given-names></name><name><surname>Ouchida</surname><given-names>M</given-names></name><name><surname>Hanabata</surname><given-names>T</given-names></name><name><surname>Aoe</surname><given-names>M</given-names></name><name><surname>Date</surname><given-names>H</given-names></name><name><surname>Gazdar</surname><given-names>AF</given-names></name><name><surname>Shimizu</surname><given-names>N</given-names></name></person-group><article-title>Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers</article-title><source>Int J Cancer</source><year>2005</year><volume>113</volume><fpage>59</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">15386433</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>TY</given-names></name><name><surname>Jong</surname><given-names>HS</given-names></name><name><surname>Song</surname><given-names>SH</given-names></name><name><surname>Dimtchev</surname><given-names>A</given-names></name><name><surname>Jeong</surname><given-names>SJ</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>NK</given-names></name><name><surname>Jung</surname><given-names>M</given-names></name><name><surname>Bang</surname><given-names>YJ</given-names></name></person-group><article-title>Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><fpage>3943</fpage><lpage>3951</lpage><pub-id pub-id-type="pmid">12813468</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Van do</surname><given-names>N</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Ernberg</surname><given-names>I</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name></person-group><article-title>Aberrant methylation of CDH13 gene in nasopharyngeal carcinoma could serve as a potential diagnostic biomarker</article-title><source>Oral Oncol</source><year>2007</year><volume>43</volume><fpage>82</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">16807071</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>AS</given-names></name><name><surname>Tsui</surname><given-names>WY</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Chu</surname><given-names>KM</given-names></name><name><surname>Chan</surname><given-names>TL</given-names></name><name><surname>Chan</surname><given-names>AS</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>So</surname><given-names>S</given-names></name><name><surname>Yuen</surname><given-names>ST</given-names></name><name><surname>Leung</surname><given-names>SY</given-names></name></person-group><article-title>Downregulation of ID4 by promoter hypermethylation in gastric adenocarcinoma</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><fpage>6946</fpage><lpage>6953</lpage><pub-id pub-id-type="pmid">14534543</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>TY</given-names></name><name><surname>Choi</surname><given-names>MC</given-names></name><name><surname>Jong</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>NK</given-names></name><name><surname>Kim</surname><given-names>WH</given-names></name><name><surname>Bang</surname><given-names>YJ</given-names></name></person-group><article-title>Aberrant methylation of integrin alpha4 gene in human gastric cancer cells</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><fpage>3474</fpage><lpage>3480</lpage><pub-id pub-id-type="pmid">14990990</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>C</given-names></name><name><surname>Yin</surname><given-names>B</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>F</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name></person-group><article-title>Promoter hypermethylation of the RUNX3 gene in esophageal squamous cell carcinoma</article-title><source>Cancer Invest</source><year>2007</year><volume>25</volume><fpage>685</fpage><lpage>690</lpage><pub-id pub-id-type="pmid">18058463</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takada</surname><given-names>T</given-names></name><name><surname>Yagi</surname><given-names>Y</given-names></name><name><surname>Maekita</surname><given-names>T</given-names></name><name><surname>Imura</surname><given-names>M</given-names></name><name><surname>Nakagawa</surname><given-names>S</given-names></name><name><surname>Tsao</surname><given-names>SW</given-names></name><name><surname>Miyamoto</surname><given-names>K</given-names></name><name><surname>Yoshino</surname><given-names>O</given-names></name><name><surname>Yasugi</surname><given-names>T</given-names></name><name><surname>Taketani</surname><given-names>Y</given-names></name><name><surname>Ushijima</surname><given-names>T</given-names></name></person-group><article-title>Methylation-associated silencing of the Wnt antagonist SFRP1 gene in human ovarian cancers</article-title><source>Cancer Sci</source><year>2004</year><volume>95</volume><fpage>741</fpage><lpage>744</lpage><pub-id pub-id-type="pmid">15471560</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khoury</surname><given-names>JD</given-names></name><name><surname>Rassidakis</surname><given-names>GZ</given-names></name><name><surname>Medeiros</surname><given-names>LJ</given-names></name><name><surname>Amin</surname><given-names>HM</given-names></name><name><surname>Lai</surname><given-names>R</given-names></name></person-group><article-title>Methylation of SHP1 gene and loss of SHP1 protein expression are frequent in systemic anaplastic large cell lymphoma</article-title><source>Blood</source><year>2004</year><volume>104</volume><fpage>1580</fpage><lpage>1581</lpage><pub-id pub-id-type="pmid">15317731</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herman</surname><given-names>JG</given-names></name><name><surname>Graff</surname><given-names>JR</given-names></name><name><surname>Myohanen</surname><given-names>S</given-names></name><name><surname>Nelkin</surname><given-names>BD</given-names></name><name><surname>Baylin</surname><given-names>SB</given-names></name></person-group><article-title>Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands</article-title><source>Proc Natl Acad Sci U S A</source><year>1996</year><volume>93</volume><fpage>9821</fpage><lpage>9826</lpage><pub-id pub-id-type="pmid">8790415</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DG</given-names></name><name><surname>Park</surname><given-names>SY</given-names></name><name><surname>You</surname><given-names>KR</given-names></name><name><surname>Lee</surname><given-names>GB</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Moon</surname><given-names>WS</given-names></name><name><surname>Chun</surname><given-names>YH</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name></person-group><article-title>Establishment and characterization of chromosomal aberrations in human cholangiocarcinoma cell lines by cross- species color banding</article-title><source>Genes Chromosomes Cancer</source><year>2001</year><volume>30</volume><fpage>48</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">11107175</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scandura</surname><given-names>JM</given-names></name><name><surname>Boccuni</surname><given-names>P</given-names></name><name><surname>Cammenga</surname><given-names>J</given-names></name><name><surname>Nimer</surname><given-names>SD</given-names></name></person-group><article-title>Transcription factor fusions in acute leukemia: variations on a theme</article-title><source>Oncogene</source><year>2002</year><volume>21</volume><fpage>3422</fpage><lpage>3444</lpage><pub-id pub-id-type="pmid">12032780</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>FH</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>YL</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>KW</given-names></name><name><surname>Chen</surname><given-names>GQ</given-names></name></person-group><article-title>c-Jun N-terminal kinase mediates AML1-ETO protein-induced connexin-43 expression</article-title><source>Biochem Biophys Res Commun</source><year>2007</year><volume>356</volume><fpage>505</fpage><lpage>511</lpage><pub-id pub-id-type="pmid">17367753</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>YB</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>YC</given-names></name><name><surname>Lubbert</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>KW</given-names></name><name><surname>Chen</surname><given-names>GQ</given-names></name></person-group><article-title>Leukemogenic AML1-ETO fusion protein upregulates expression of connexin 43: the role in AML 1-ETO-induced growth arrest in leukemic cells</article-title><source>J Cell Physiol</source><year>2006</year><volume>208</volume><fpage>594</fpage><lpage>601</lpage><pub-id pub-id-type="pmid">16741927</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deininger</surname><given-names>M</given-names></name><name><surname>Buchdunger</surname><given-names>E</given-names></name><name><surname>Druker</surname><given-names>BJ</given-names></name></person-group><article-title>The development of imatinib as a therapeutic agent for chronic myeloid leukemia</article-title><source>Blood</source><year>2005</year><volume>105</volume><fpage>2640</fpage><lpage>2653</lpage><pub-id pub-id-type="pmid">15618470</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>GW</given-names></name></person-group><article-title>The function of the protein tyrosine phosphatase SHP-1 in cancer</article-title><source>Gene</source><year>2003</year><volume>306</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">12657462</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chim</surname><given-names>CS</given-names></name><name><surname>Fung</surname><given-names>TK</given-names></name><name><surname>Cheung</surname><given-names>WC</given-names></name><name><surname>Liang</surname><given-names>R</given-names></name><name><surname>Kwong</surname><given-names>YL</given-names></name></person-group><article-title>SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway</article-title><source>Blood</source><year>2004</year><volume>103</volume><fpage>4630</fpage><lpage>4635</lpage><pub-id pub-id-type="pmid">14976049</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chim</surname><given-names>CS</given-names></name><name><surname>Wong</surname><given-names>KY</given-names></name><name><surname>Loong</surname><given-names>F</given-names></name><name><surname>Srivastava</surname><given-names>G</given-names></name></person-group><article-title>SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma: implications for epigenetic activation of the Jak/STAT pathway</article-title><source>Leukemia</source><year>2004</year><volume>18</volume><fpage>356</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">14614518</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deininger</surname><given-names>M</given-names></name><name><surname>Buchdunger</surname><given-names>E</given-names></name><name><surname>Druker</surname><given-names>BJ</given-names></name></person-group><article-title>The development of imatinib as a therapeutic agent for chronic myeloid leukemia</article-title><source>Blood</source><year>2005</year><volume>105</volume><fpage>2640</fpage><lpage>2653</lpage><pub-id pub-id-type="pmid">15618470</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Fig. 1</label><caption><p>PCR product images of the <italic>DAB2IP</italic>, <italic>DLC-1</italic>, <italic>H-Cadherin</italic>, <italic>ID4</italic>, <italic>Integrin &#x003b1;4</italic>, <italic>RUNX3</italic>, <italic>SFRP1</italic>, and <italic>SHP1</italic> genes in normal peripheral bloods, acute myeloid leukemias, and chronic myeloid leukemias.</p><p>N, normal peripheral blood; A, acute myeloid leukemia; C, chronic myeloid leukemias; U, amplified products used as primers for the unmethylated sequence in normal peripheral blood; M, amplified products used as primers for the methylated sequence.</p></caption><graphic xlink:href="jkms-24-493-g001"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Sequences of primers and PCR conditions</p></caption><graphic xlink:href="jkms-24-493-i001"/><table-wrap-foot><fn><p>PCR, polymerase chain reaction; temp., temperature; UF, unmethylated forward-sequence; UR, unmethylated reverse-sequence; MF, methylated forward-sequence; MR, methylated reverse-sequence.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Methylation frequencies in normal peripheral bloods, acute myeloid leukemias, and chromic myeloid leukemias</p></caption><graphic xlink:href="jkms-24-493-i002"/><table-wrap-foot><fn><p><sup>*</sup><italic>P</italic>&#x0003c;0.05.</p><p>N, normal peripheral bloods; A, acute myeloid leukemia; C, chronic myeloid leukemia.</p></fn></table-wrap-foot></table-wrap></floats-group></article>